کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3285478 | 1209230 | 2006 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
NF-κBCAINOSTNBSMAPK - MAPKTrinitrobenzene sulfonic acid - اسید سولفونیک Trinitrobenzenesulfasalazine - سولفاسالازینClinical Activity Index - شاخص فعالیت کلینیکیnuclear factor-κB - فاکتور هسته ای κBnitric oxide synthase - نیتریک اکسید سنتازmitogen-activated protein kinase - پروتئین کیناز فعال با mitogenUlcerative colitis - کولیت اولسراتیو
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Background & Aims: Curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis (UC). The aim in this trial was to assess the efficacy of curcumin as maintenance therapy in patients with quiescent ulcerative colitis (UC). Methods: Eighty-nine patients with quiescent UC were recruited for this randomized, double-blind, multicenter trial of curcumin in the prevention of relapse. Forty-five patients received curcumin, 1g after breakfast and 1g after the evening meal, plus sulfasalazine (SZ) or mesalamine, and 44 patients received placebo plus SZ or mesalamine for 6 months. Clinical activity index (CAI) and endoscopic index (EI) were determined at entry, every 2 months (CAI), at the conclusion of 6-month trial, and at the end of 6-month follow-up. Results: Seven patients were protocol violators. Of 43 patients who received curcumin, 2 relapsed during 6 months of therapy (4.65%), whereas 8 of 39 patients (20.51%) in the placebo group relapsed (P = .040). Recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo (P = .049). Furthermore, curcumin improved both CAI (P = .038) and EI (P = .0001), thus suppressing the morbidity associated with UC. A 6-month follow-up was done during which patients in both groups were on SZ or mesalamine. Eight additional patients in the curcumin group and 6 patients in the placebo group relapsed. Conclusions: Curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent UC. Further studies on curcumin should strengthen our findings.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Gastroenterology and Hepatology - Volume 4, Issue 12, December 2006, Pages 1502-1506
Journal: Clinical Gastroenterology and Hepatology - Volume 4, Issue 12, December 2006, Pages 1502-1506
نویسندگان
Hiroyuki Hanai, Takayuki Iida, Ken Takeuchi, Fumitoshi Watanabe, Yasuhiko Maruyama, Akira Andoh, Tomoyuki Tsujikawa, Yosihihide Fujiyama, Keiichi Mitsuyama, Michio Sata, Masami Yamada, Yasushi Iwaoka, Kazunari Kanke, Hideyuki Hiraishi, Kazuhisa Hirayama,